Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle

Journal of Applied Physiology

Volumn 104, Issue 4, 2008, Pages 1154-1160

  Lundby, Carsten ^a,b,c   Hellsten, Ylva ^a,d   Jensen, Mie B F ^a,d   Munch, Anders S ^a,d   Pilegaard, Henriette ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c Department of Sport Science ^*  (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Angiogenesis; Cancer; Hypertrophy; rHuEpo; Tumor; Vascular endothelial growth factor

Indexed keywords

ERYTHROPOIETIN RECEPTOR; IRON; MESSENGER RNA; MYOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ACUTE DRUG ADMINISTRATION; ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM; GENE EXPRESSION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE CAPILLARY; MUSCLE HYPERTROPHY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SARCOLEMMA; SINGLE DRUG DOSE; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER;

ADULT; CAPILLARIES; CELL PROLIFERATION; DNA PRIMERS; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; ERYTHROPOIETIN, RECOMBINANT; HORMONES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE FIBERS; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 41949137980     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01211.2007     Document Type: Article

References (30)

1. Alvarez Arroyo MV, Castilla MA, Gonzalez Pacheco FR, Tan D, Riesco A, Casado S, Caramelo C. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol 9: 1998-2004, 1998.
2. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91: 3974-3978, 1994.
3. Bellomo M, Marini H, Adamo EB, Catania MA, Mannucci C, Squadrito F, Marini R, Giuffrida R, Grasso G, Buemi M, Caputi AP, Giacca M, Calapai G. Vascular endothelial growth factor induces brain erythropoietin expression? Funct Neurol 21: 87-91, 2006.
4. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019, 2002.
5. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70: 246-250, 2006.
6. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9: 18-30, 2004.
7. Fischer C, Carmeliet P, Conway ME. VEGF inhibitors make blood. Nat Med 12: 732-734, 2006.
8. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 68: 299-306, 2005.
9. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333, 2002.
10. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449-489, 1992.
11. Jensen L, Pilegaard H, Neufer PD, Hellsten Y. Effect of acute exercise and exercise training on VEGF splice variants in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol 287: R397-R402, 2004.
12. Li Y, Lu Z, Keogh CL, Yu SP, Wei L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 5: 1043-1054, 2007.
13. Lundby C, Nordsborg N, Kusuhara K, Kristensen KM, Neufer PD, Pilegaard H. Gene expression in human skeletal muscle: alternative normalization method and effect of repeated biopsies. Eur J Appl Physiol 95: 351-360, 2005.
14. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JAL, Robach P. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 578: 309-314, 2007.
15. Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RHG, Bloch W. Role of erythropoetin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol 290: H331-H340, 2006.
16. Pilegaard H, Ordway GA, Saltin B, Neufer PD. Transcriptional regulation of gene expression in human skeletal muscle during recovery from exercise. Am J Physiol Endocrinol Metab 279: E806-E814, 2000.
17. Prior BM, Lloyd PG, Yang HT, Terjung RL. Exercise induced vascular remodeling. Med Sci Sports Exerc 31: 26-33, 2003.
18. Psilander N, Damsgaard R, Pilegaard H. Resistance exercise alters MRF and IGF-I mRNA content in human skeletal muscle. J Appl Physiol 95: 1038-1044, 2003.
19. Ratajczak J, Majka M, Kijowski J, Baj M, Pan ZK, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 115: 195-204, 2001.
20. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 33: 891-896, 2003.
21. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93: 2627-2636, 1999.
22. Robach P, Cairo G, Gelfi C, Bernuzzi F, Pilegaard H, Vigano A, Santambrogio P, Cerretelli P, Calbet JAL, Moutereau S, Lundby C. Strong iron demand during hypoxia-induced erythropoiesis is associated with down-regulation of iron-related proteins and myoglobin in human skeletal muscle. Blood 109: 4724-4731, 2007.
23. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3: 1009-1013, 2001.
24. Saltin B, Gollnick P. Skeletal muscle adaptability: significance for metabolism and performance. In: Handbook of Physiology. Skeletal Muscle. Bethesda, MD: Am Physiol Soc, 1983, sect. 10, chapt. 19, p. 555-631.
25. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Comm 308: 990-994, 2003.
26. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35: 1732-1737, 2004.
27. WHO. Energy and protein requirements. WHO Technical Report Series 71-95, 1985.
28. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031-1033, 2004.
29. Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, Okamura K. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 8: 441-446, 2002.
30. Zhang D, Zhang F, Zhang Y, Gao X, Li C, Ma W, Cao K. Erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat model of myocardial infarction. Cardiology 108: 228-236, 2006.